Cerefolin Brain Wellness™ | For Healthcare Professionals

Healthcare Professionals

**Cerefolin Brain Wellness™**
Targeted nutrition to support mild cognitive impairment

Help protect brain health using targeted nutrition

Patients are coming to you worried about their brain health. Reassure them with our product containing clinically tested* ingredients.

L-methylfolate calcium (active folate) supports acetylcholine production to help memory and cognitive health.⁶
N-acetyl-l-cysteine (NAC) elevates glutathione levels to protect the brain against oxidative stress. ¹²
Methylcobalamin (vitamin B12) aids in myelin production, neuroplasticity, and neuronal repair, enhancing overall brain health.^4-6

See Product Details

Using targeted nutrition for homocysteine management to slow mild cognitive impairment

In a clinical study, Cerefolin Brain Wellness™* has been proven to slow the progression of brain atrophy—cortical and white matter—in patients with hyperhomocysteinemia (HHcy ≥12µmol/L), compared to patients not on the therapy and without elevated levels of homocysteine.^1*

See More Clinical Data

Same Efficacy, Free From Major Allergens

Cerefolin Brain Wellness™ previously known and studied as CerefolinNAC®, is the same trusted and effective product that is now free from major allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, sesame and soy), dyes and colorants.

See Product Details

Disclaimers

Cerefolin Brain Wellness™ is a targeted nutrition product for the clinical dietary management of mild cognitive impairment with hyperhomocysteinemia and is specially formulated to meet the distinctive nutritional requirements for this condition. Use only under medical supervision.

* Cerefolin Brain Wellness™, formerly known and studied as CerefolinNAC®, is the same trusted and effective product that is now free from major allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, sesame and soy), dyes, and colorants.

† By submitting this information, I hereby give Alfasigma USA, Inc. authorization to release, reproduce, use or distribute information about me, in original or modified form, for promotional and educational purposes in all forms of media, including print, broadcast or Internet. This information may include my medical information if I choose to submit any. I understand my information may be shared with a third party working on Alfasigma USA, Inc.’s behalf for promotional or educational purposes. I also understand that I may be contacted by this third party or Alfasigma USA, Inc. for more information.

^†† This product should be taken under medical supervision, and you should consult your healthcare provider before taking this for mild cognitive impairment.

References

Shankle WR, et al. J Alzheimer’s Dis. 2016 Oct 4;54(3):1073-1084
Shankle WR, et al. J Aging Res Clin Prac. 2013
Hara J, et al. Nutr Health Aging. 2015
Alfasigma USA. Data on File. PLUS Program: Patient Survey Results 2012. USA
Data on file. Support data 2019-2024. Alfasigma USA.
Chan A, et al. J Nutr Health Aging 2008;12(4):252-61.
de Jager CA. et al. Int J Geriatr Psychiatry. 2012 Jun:27(6):592-600.
Merrill E, et al. Am. J. Epidemiol. 2005 Oct;162(7):644-53.
Altern Med Rev 2000 Oct;5(5):467-71.
de Jager CA. Neurobiol Aging 2014;35(suppl 2):535-9.
Atkuri KR, et al. Curr Opin Pharmacol. 2007. 2007
N-acetylcysteine. Monograph. Alt Med Rev. 2000
Antoniades C, et al. Circulation. 2006.
Calderón-Ospina CA, et al. CNS Neurosci Ther. 2020.
Kimura, A.M et al. Alzheimer’s Dement. 2021.
Rogers JD, et al. Arch Neurol. 2003 Jan;60(1):59-64.
Smith AD, et al. J Alzheimer’s Dis.
Seshadri S, et al. N Engl J Med. 2002.
Yao Y, et al. J Geriatr Cardiol. 2017.
Diaz-Arrastia R, et al. Arch Neurol. 2000.
Keller, A.C., et al. J. Appl. Physiol. 2019.
Zhu Z, et al. Climacteric. 2020.
Estrada, D.A. et al. Am. J. Hematol. 2001.
Luzzi S, et al. Biomedicines. 2022.
Diekman, M. J. M., et al. Clin. Endocrinol. (Oxf) 2001.
Paknahad Z, et al. Int J Prev Med. 2012.
Desouza, C, et al. Drugs. 2002.
P. S. Myles et al. Br. J. Anaesth. 2008.
Fallah S, et al. J Clin Lab Anal. 2012.
Lerman, et al. AJMS., 2022.
Troen AM, et al. Proc Natl Acad Sci U S A. 2003.
Haj Mouhamed D, et al. Clin Chem Lab Med. 2011.

Healthcare Professionals

Product Information

Clinical Research

How to Prescribe

Help protect brain health using targeted nutrition

Using targeted nutrition for homocysteine management to slow mild cognitive impairment

Same Efficacy, Free From Major Allergens

Stay Up to Date

Disclaimers

References